retatrutide triple agonist glp-1 gip glucagon phase 2 nejm 2023 Efficacy and safety of retatrutide, a GIP, GLP-1, and receptor agonist, in people with type diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, 3 Peptides for Weight Loss Research:

Overall, the pattern suggests that inter-individual variability in composite redox indices, particularly glutathione-based measures, may statistically co-vary with changes in selected functional measures in physically active older adults, but confirmation in larger, adequately powered samples specifically designed to test these relationships is required

Research is required to determine the molecular mechanism underlying the relationship between of l-carnitine on blood pressure

Long-term data on retatrutide is still pretty limited

Am J Physiol 251(6 Pt 2):H1106H1110

It is also important to consider the use of compounded medications

In light of this information, NCL offers this advice to consumers when considering GLP-1 treatment options: Before seeking treatment with a GLP-1 drug, talk to your doctor or health provider to determine if you are a candidate for treatment based on your risk factors and degree of obesity